MX379201B - Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. - Google Patents
Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.Info
- Publication number
- MX379201B MX379201B MX2018008640A MX2018008640A MX379201B MX 379201 B MX379201 B MX 379201B MX 2018008640 A MX2018008640 A MX 2018008640A MX 2018008640 A MX2018008640 A MX 2018008640A MX 379201 B MX379201 B MX 379201B
- Authority
- MX
- Mexico
- Prior art keywords
- diaza
- carboxyethyl
- spiro
- oxo
- amino
- Prior art date
Links
- AKFDWOCIAWTVNG-UHFFFAOYSA-N 3-(8-amino-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)propanoic acid Chemical class C(=O)(O)CCN1C(NC2(C1)CCC(CC2)N)=O AKFDWOCIAWTVNG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151011 | 2016-01-13 | ||
| PCT/EP2017/025004 WO2017121646A1 (en) | 2016-01-13 | 2017-01-13 | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008640A MX2018008640A (es) | 2018-11-19 |
| MX379201B true MX379201B (es) | 2025-03-11 |
Family
ID=55129632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008640A MX379201B (es) | 2016-01-13 | 2017-01-13 | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US20170197919A1 (https=) |
| EP (2) | EP3722283A1 (https=) |
| JP (2) | JP6862457B2 (https=) |
| KR (1) | KR20180100592A (https=) |
| CN (1) | CN108699005B (https=) |
| AR (1) | AR107361A1 (https=) |
| AU (1) | AU2017207467B2 (https=) |
| BR (1) | BR112018014302B1 (https=) |
| CA (1) | CA3011175C (https=) |
| CL (1) | CL2018001913A1 (https=) |
| CO (1) | CO2018008445A2 (https=) |
| CY (1) | CY1122882T1 (https=) |
| DK (1) | DK3402783T3 (https=) |
| EA (1) | EA037649B1 (https=) |
| EC (1) | ECSP18060820A (https=) |
| ES (1) | ES2803354T3 (https=) |
| HR (1) | HRP20200656T1 (https=) |
| HU (1) | HUE049374T2 (https=) |
| IL (1) | IL260495B (https=) |
| LT (1) | LT3402783T (https=) |
| MX (1) | MX379201B (https=) |
| PL (1) | PL3402783T3 (https=) |
| PT (1) | PT3402783T (https=) |
| RS (1) | RS60223B1 (https=) |
| SI (1) | SI3402783T1 (https=) |
| TW (1) | TWI635081B (https=) |
| WO (1) | WO2017121646A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3402784T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
| SI3402782T1 (sl) | 2016-01-13 | 2020-11-30 | Grunenthal Gmbh | 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati |
| CA3011176C (en) | 2016-01-13 | 2023-09-19 | Grunenthal Gmbh | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| CA3011180A1 (en) | 2016-01-13 | 2017-07-20 | Grunenthal Gmbh | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| BR112018014302B1 (pt) | 2016-01-13 | 2023-10-17 | Grünenthal GmbH | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| KR102866751B1 (ko) * | 2020-06-09 | 2025-10-01 | 삼성디스플레이 주식회사 | 축합환 화합물을 포함한 발광 소자 및 상기 발광 소자를 포함한 전자 장치 |
| WO2023011422A1 (zh) * | 2021-08-02 | 2023-02-09 | 上海枢境生物科技有限公司 | 氧杂螺环类衍生物、制备方法及其用途 |
| US20240400537A1 (en) | 2023-04-25 | 2024-12-05 | Gruenenthal Gmbh | Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2734265B1 (fr) | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant |
| RU2268883C2 (ru) | 2001-04-18 | 2006-01-27 | Эро-Селтик, С.А. | Аналоги ноницептина и фармацевтическая композиция на их основе |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| DE10210195B4 (de) | 2002-03-07 | 2005-12-15 | Schwarz Pharma Ag | Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1628978A2 (en) | 2003-05-23 | 2006-03-01 | Zealand Pharma A/S | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| JO2676B1 (en) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| CN101553474B (zh) | 2006-10-19 | 2013-02-27 | 霍夫曼-拉罗奇有限公司 | 作为糖尿病用11b-HSD1抑制剂的咪唑啉酮和咪唑烷酮衍生物 |
| CA2683598C (en) | 2007-04-09 | 2015-11-17 | Janssen Pharmaceutica Nv | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| CA2719735A1 (en) * | 2008-03-27 | 2009-10-01 | Gruenenthal Gmbh | Substituted 4-aminocyclohexane derivatives |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
| WO2015192039A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
| BR112018014302B1 (pt) | 2016-01-13 | 2023-10-17 | Grünenthal GmbH | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| CA3011180A1 (en) | 2016-01-13 | 2017-07-20 | Grunenthal Gmbh | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| SI3402782T1 (sl) | 2016-01-13 | 2020-11-30 | Grunenthal Gmbh | 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati |
| SI3402784T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
-
2017
- 2017-01-13 BR BR112018014302-2A patent/BR112018014302B1/pt not_active IP Right Cessation
- 2017-01-13 HU HUE17700474A patent/HUE049374T2/hu unknown
- 2017-01-13 PL PL17700474T patent/PL3402783T3/pl unknown
- 2017-01-13 AU AU2017207467A patent/AU2017207467B2/en not_active Ceased
- 2017-01-13 SI SI201730241T patent/SI3402783T1/sl unknown
- 2017-01-13 HR HRP20200656TT patent/HRP20200656T1/hr unknown
- 2017-01-13 TW TW106101123A patent/TWI635081B/zh active
- 2017-01-13 MX MX2018008640A patent/MX379201B/es unknown
- 2017-01-13 LT LTEP17700474.4T patent/LT3402783T/lt unknown
- 2017-01-13 WO PCT/EP2017/025004 patent/WO2017121646A1/en not_active Ceased
- 2017-01-13 RS RS20200519A patent/RS60223B1/sr unknown
- 2017-01-13 DK DK17700474.4T patent/DK3402783T3/da active
- 2017-01-13 PT PT177004744T patent/PT3402783T/pt unknown
- 2017-01-13 EA EA201891610A patent/EA037649B1/ru unknown
- 2017-01-13 US US15/405,482 patent/US20170197919A1/en not_active Abandoned
- 2017-01-13 EP EP20155667.7A patent/EP3722283A1/en not_active Withdrawn
- 2017-01-13 KR KR1020187021561A patent/KR20180100592A/ko not_active Withdrawn
- 2017-01-13 CN CN201780006500.8A patent/CN108699005B/zh not_active Expired - Fee Related
- 2017-01-13 JP JP2018536433A patent/JP6862457B2/ja not_active Expired - Fee Related
- 2017-01-13 CA CA3011175A patent/CA3011175C/en active Active
- 2017-01-13 EP EP17700474.4A patent/EP3402783B1/en active Active
- 2017-01-13 ES ES17700474T patent/ES2803354T3/es active Active
- 2017-01-13 AR ARP170100096A patent/AR107361A1/es unknown
-
2018
- 2018-05-15 US US15/979,932 patent/US20180273491A1/en not_active Abandoned
- 2018-07-09 IL IL260495A patent/IL260495B/en unknown
- 2018-07-13 CL CL2018001913A patent/CL2018001913A1/es unknown
- 2018-08-13 CO CONC2018/0008445A patent/CO2018008445A2/es unknown
- 2018-08-13 EC ECSENADI201860820A patent/ECSP18060820A/es unknown
- 2018-12-03 US US16/207,676 patent/US20190100497A1/en not_active Abandoned
-
2019
- 2019-06-24 US US16/450,406 patent/US10793528B2/en active Active
-
2020
- 2020-05-06 CY CY20201100416T patent/CY1122882T1/el unknown
- 2020-08-31 US US17/007,374 patent/US20200399226A1/en not_active Abandoned
-
2021
- 2021-03-01 US US17/188,802 patent/US20210214315A1/en not_active Abandoned
- 2021-03-30 JP JP2021056938A patent/JP7148665B2/ja active Active
-
2023
- 2023-01-30 US US18/102,983 patent/US20230183184A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122818T1 (el) | Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου | |
| MX379201B (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX378607B (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2015017671A (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones viricas y otras enfermedades. | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EA202090270A1 (ru) | Новые замещенные производные ксантина | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |